Paracetamol + Phenylephrine + CPM + Sodium Citrate + Menthol

This suspension belongs to the Suspensions category within the Anti-Pyretic, Cough & Cold, and Pediatric Care therapeutic segments. It is clinically positioned above the standard Paracetamol + Phenylephrine + CPM three-active formula through the addition of two pharmacologically meaningful components:

• Paracetamol — antipyretic and analgesic; the foundational component
• Phenylephrine HCl — alpha-1 adrenergic nasal decongestant
• Chlorpheniramine Maleate — H1 antihistamine for rhinorrhea, sneezing, and allergic symptoms
• Sodium Citrate 60mg — mucolytic/expectorant adjunct that alkalinizes and liquefies thick mucus
• Menthol 1mg — cooling counterirritant that soothes inflamed upper airways and reduces cough reflex hypersensitivity

The five-component rationale is clinically coherent — each molecule addresses a distinct pathophysiological component of the pediatric cold presentation. For pharmaceutical marketing companies, this formula provides a stronger prescriber story and higher MRP justification than commodity three-active cold suspensions while using the same manufacturing infrastructure.

Saar Biotech manufactures this formulation from our manufacturing facility in Baddi in three validated strength combinations to cover the full pediatric age and weight range.

Manufacturing a five-active suspension with consistent dose uniformity across all five components requires more rigorous process control than a three-active formula. Our formulation team has optimized the suspending agent, pH buffer, and mixing sequence to ensure stability and uniformity of all five actives simultaneously.

• Five-API Suspension Uniformity: Paracetamol is a suspended solid; Sodium Citrate and CPM are dissolved; Phenylephrine and Menthol are present in their respective salt and dissolved forms. Our mixing sequence and in-process controls ensure uniform distribution of all five actives throughout the suspension matrix, with consistent re-dispersibility after shaking.
• Menthol Solubilization and Retention: Menthol is volatile and crystalline. Our process incorporates it as a pharmaceutical-grade solubilized form within the suspension base, preventing recrystallization within the bottle during the product’s shelf life.
• Three-Strength Capability: All three strength variants share the same Sodium Citrate 60mg + Menthol 1mg base, with only the Paracetamol, Phenylephrine, and CPM concentrations varying. This enables efficient multi-SKU production from a single validated base formula.
• Pediatric Palatability: Mango and orange flavour systems are calibrated to mask the combined bitter and astringent notes of the five-active combination while delivering the expected sweet cold suspension taste that drives pediatric compliance.

This five-active suspension is manufactured and supplied by Saar Biotech for multi-symptom pediatric upper respiratory illness management:

• Fever & Body Ache: Paracetamol’s antipyretic action reduces fever from viral cold and flu infections.
• Nasal Congestion: Phenylephrine provides targeted vasoconstriction to open blocked nasal passages.
• Runny Nose & Sneezing: CPM’s H1 blockade reduces histamine-driven rhinorrhea and sneezing.
• Thick Mucus & Congestion: Sodium Citrate alkalinizes and thins viscous mucus, improving its mobility and clearance.
• Upper Airway Irritation: Menthol soothes inflamed pharyngeal and nasal mucosa, reducing the irritative cough trigger.

Schedule H — Requires valid medical prescription. Concurrent paracetamol products must be strictly avoided.

Five-Component Clinical Mechanism

Paracetamol inhibits central prostaglandin synthesis in the hypothalamic thermoregulatory center, reducing fever and raising the pain threshold. Phenylephrine HCl stimulates alpha-1 adrenergic receptors on nasal submucosal vessels, causing vasoconstriction and mucosal deconge­stion. Chlorpheniramine Maleate competitively blocks H1 histamine receptors, suppressing allergic rhinorrhea, sneezing, and ocular symptoms. Sodium Citrate alkalinizes bronchial and nasal secretions, reducing mucus gel viscosity through ionization of mucoprotein disulfide bonds and partial pH normalization of acidified respiratory secretions during infection. Menthol activates TRPM8 cold-receptor channels in the nasopharyngeal mucosa and reduces nociceptor sensitivity through kappa-opioid receptor modulation, delivering a soothing cooling sensation that desensitizes hypersensitive cough-triggering nerve endings.

Manufacturing Integrity

• Five-API Chemical Compatibility: Each of the five components must remain chemically stable in a shared aqueous suspension vehicle across 24 months. Saar Biotech’s pH and excipient selection is validated for simultaneous compatibility of all five molecules — including the specific pH range optimal for Phenylephrine stability, Paracetamol hydrolysis prevention, and Menthol solubility maintenance.
• Suspension Consistency: The Paracetamol solid phase must remain uniformly dispersed with robust re-dispersibility. Our suspending agent system supports consistent settling behavior and rapid re-suspension on shaking — critical for weight-based pediatric dosing reliability.

• Enhanced Clinical Differentiation Over Three-Active Formulas: The five-active formula addresses two additional symptom pathways (mucus viscosity and airway cooling) that the standard PCM + Phenylephrine + CPM formula leaves unaddressed. This translates to a clinically differentiated product that prescribers can recommend with greater confidence in pediatric presentations with concurrent thick mucus and airway irritation.
• Sodium Citrate as a Mucolytic Signal: Prescribers familiar with Sodium Citrate’s mucolytic action in expectora­tion syrups recognize its rationale immediately when it appears in a cold formula. This familiarity supports rapid prescriber adoption without extensive detailing.
• Menthol as a Patient Experience Differentiator: The immediate cooling sensation from Menthol 1mg per 5ml creates a distinct, noticeable sensory experience from the first dose that parents and children associate with therapeutic action — building brand recall and repeat prescription behavior.
• Premium Pricing Justification: A five-active formula with documented clinical rationale for each component supports a meaningfully higher MRP than three-active commodity cold suspensions, improving margin for B2B partners without requiring a fundamentally different manufacturing or supply chain investment.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Paracetamol + Phenylephrine + CPM + Sodium Citrate + Menthol Suspension from our oral suspension manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Controlled oral suspension manufacturing area with high-shear mixing, automated filling, capping, and labeling for 30ml and 60ml presentations.
• Capacity: Scalable from brand-entry launches to large seasonal batches; 160×60ml and 200×60ml distributor dispatch configurations.
• Quality Lab: In-house GLP-certified lab with HPLC for Paracetamol, Phenylephrine, CPM; titrimetric for Sodium Citrate; GC for Menthol; plus suspension uniformity, pH, viscosity, MLT, and fill volume checks.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 30ml and 60ml amber PET bottles; sticker label, metallic label, silver leafing, drip-off embossed carton, measuring cup, tricolour measuring cap, printed cap, company-logo PP cap, with/without carton.
• MOQ: 5,000–10,000 units per SKU across all three strength variants.

1. Shake Well Before Every Dose: Paracetamol in this formulation is a suspended solid — consistent shaking before each 5ml dose is the most critical patient instruction. The suspension must be completely re-dispersed before measuring.
2. Store Below 30°C: Elevated temperatures affect both Menthol solubility (risk of crystallization) and Phenylephrine stability (oxidative degradation). Do not expose to direct sunlight or excessive heat during distribution.
3. Do Not Freeze: Sub-zero temperatures irreversibly alter the suspension matrix and may cause Menthol precipitation and Paracetamol sedimentation that cannot be recovered by shaking.
4. Measuring Cup Required: Weight-based Paracetamol dosing demands accurate measurement. All 60ml packs must be supplied with a calibrated measuring cup.

Every commercial batch is released only after a full five-active analytical protocol in our GLP-certified QC laboratories in Baddi:

• HPLC Assay (3 actives): Paracetamol, Phenylephrine HCl, and CPM confirmed at label claim.
• Sodium Citrate Titrimetric Assay: Confirmed at 60mg per 5ml specification.
• Menthol GC Analysis: Confirmed at 1mg per 5ml specification.
• Suspension Uniformity & Re-Dispersibility: Multi-point sampling confirms dose consistency throughout the fill volume.
• pH & Viscosity: Monitored for stability and correct suspension behavior.
• MLT: IP oral suspension standards for pediatric product safety.
• Certificate of Analysis (COA): Issued with every B2B batch.

The safety profile is governed primarily by Paracetamol (hepatotoxicity risk with overdose — strict weight-based dosing mandatory; no concurrent paracetamol products), CPM (sedation — avoid driving and alcohol), and Phenylephrine (cardiovascular caution — avoid in severe hypertension and with MAO inhibitors). Sodium Citrate and Menthol at the stated doses are well-tolerated with no significant known adverse effects. Concurrent use of other paracetamol-containing products is strictly contraindicated.

For third-party manufacturing enquiries, private-label contracts, or to request pricing for Paracetamol + Phenylephrine + CPM + Sodium Citrate + Menthol Suspension, please use the B2B enquiry form below.